Recordati S.p.A. : reports revenue and earnings in the first nine months 2008

Furthermore, the Board of Directors resolved to grant 3,875,000 stock options under the 2006-2009 Stock Option Plan approved by the Shareholders' Meeting of 6 April 2006, to 95 group managers (see table attached). The options may be exercised only if certain consolidated net income objectives are reached. The strike price is the average market price of the share over the period between the date of grant and the same day of the preceding month. The characteristics of the plan are described in the information document issued on 17 September 2007 and available on the company's website http://www.recordati.com/rec_en/investors/releases/2007/2007-09-17/2007-09-17.pdf .

Management comments

"During the year important initiatives for the development of our group were undertaken", stated Giovanni Recordati, Chairman and Chief Executive Officer. "With the acquisition of FIC and now of Yeni Ilaç we have secured a direct presence in Russia and in Turkey, two fast growing pharmaceutical markets. With the approval of our new antihypertensive product and the license to pitavastatin obtained from Kowa we have reinforced our product portfolio. The transactions completed this year, together with the acquisition of Orphan Europe in 2007, and further ongoing initiatives which we expect to complete shortly, allow us to be confident of our development into the future. Therefore, on the 18th of December we will present our 2009-2011 business plan, which will illustrate the development of our business and our strategy for maintaining profitability in the future, to the financial community."

Conference call

Recordati will be hosting a conference call today 29 October 2008 at 4.00 pm Italian time (3.00 pm London time, 10.00 am New York time). The conference ID is 68407080 and dial-in numbers are:

Italy 39 02 36005955

UK 44 (0) 1452 587 427

USA 18665516755

France 33 (0) 170751217

Germany 49 (0) 6922227071

A set of slides which will be referred to during the call will be available on our website www.recordati.com under Investors/Company Presentations.

Callers are invited to dial-in 10 minutes before conference time and state the ID number 68407080. If conference operator assistance is required during the connection please digit * followed by 0 or call 44 1452 553 456. A recording of the conference call will be placed on the website www.recordati.com .

Recordati, established in 1926, is a European pharmaceutical group, listed on the Italian Stock Exchange (Reuters RECI.MI, Bloomberg REC IM, ISIN IT 0003828271), dedicated to the research, development, manufacturing and marketing of pharmaceuticals, with headquarters in Milan, Italy, operations in the main European countries, and a total staff of over 2,400. A European field force of over 1,300 medical representatives promotes a wide range of innovative pharmaceuticals, both proprietary and under license, in a number of therapeutic areas including a specialized business dedicated to treatments for rare diseases. Recordati's current and growing coverage of the European pharmaceutical market makes it a partner of choice for new product licenses from companies which do not have European marketing organizations. Recordati is committed to the research of new drug entities within the cardiovascular and urogenital therapeutic areas in which its research team has proven scientific competence and a track record of discovery and development of original drugs, the most recent of which, lercanidipine, a latest generation calcium channel blocker for the treatment of hypertension, is the company's leading product. Consolidated revenue for 2007 was EUR 628.4 million, operating income was EUR 131.5 million and net income was EUR 84.9 million.